IOR-01 - Efficacy and Safety of Fremanezumab for the Preventive Treatment of Episodic Migraine in Children and Adolescents: a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
IOR-02 - Patient perspectives of migraine symptomology: Insights from exit interviews from the anti-PACAP antibody phase 2 HOPE trial for migraine prevention
Presenting Author: Richard B. Lipton, MD – The Saul R. Korey Department of Neurology, Department of Psychiatry and Behavioral Science, and Department of Epidemiology and Population Health, Montefiore Headache Centre, Albert Einstein College of Medicine, New York, NY, USA
8:50am – 9:00am CST
IOR-03 - Efficacy and Safety of Symbravo® (MoSEICTM meloxicam and rizatriptan) in Participants With Migraine Experiencing an Inadequate Response to Oral CGRP Inhibitors: Topline Results From the EMERGE Trial
Presenting Author: Richard B. Lipton, MD – The Saul R. Korey Department of Neurology, Department of Psychiatry and Behavioral Science, and Department of Epidemiology and Population Health, Montefiore Headache Centre, Albert Einstein College of Medicine, New York, NY, USA
9:00am – 9:10am CST
IOR-04 - Durable Pain Relief in Headache Patients Following 60-Day Peripheral Nerve Stimulation: Results from a Prospective, Single-Arm Study
IOR-05 - Results From a Phase 3 Bridging Study of CT-132, an Investigational Prescription Digital Therapeutic, in Patients With Episodic Migraine Receiving Calcitonin Gene-Related Peptide Inhibitors
Presenting Author: Alex Kuka, PhD – Click Therapeutics Inc
9:20am – 9:30am CST
IOR-06 - Characterizing Within Participant Consistency of Prodromal Symptoms in Migraine: Results from the PRODROME Trial Screening Period
OR-20 - Association of migraine and vasomotor symptom severity and duration among naturally menopausal women in midlife women in Nurses’ Health Study II
Presenting Author: Holly M. Crowe, PhD, MPH – Brigham and Women's Hospital/Harvard Medical School
3:35pm – 3:45pm CST
OR-21 (Frontier) - Calcitonin Gene-Related Peptide Inhibitor and Triptan Prescription Patterns in a Large Health System and Relationship to Ischemic Stroke Diagnosis (2018-2024)
OR-24 - Traumatic Brain Injury Recovery Prediction with Harmonized Brain MRI and CT
Presenting Author: Yiming Che, PhD – Arizona State University
3:25pm – 3:35pm CST
OR-25 - Severity of non-headache physical, emotional, and cognitive symptoms is associated with future improvement of acute post-traumatic headache attributed to mild traumatic brain injury
DB-03 - OnabotulinumtoxinA reduces percentage of activated dural pro-inflammatory macrophages and increases percentage of dural anti-inflammatory macrophages in response to CSD in female mice.
Presenting Author: Aaron J. Schain, PhD – Beth Israel Deaconess Medical Center / Harvard Medical School
5:54pm – 6:04pm CST
DB-04 - Activation of Protease-Activated Receptor 2 Induces Hyperexcitability in Human Sensory Neurons